SPTX
Seaport Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-34/100
Last price
17.50
▲ 0.13 (0.78%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
17.28
Prev close
17.37
Day high
18.29
Day low
17.07
Volume
165.09K
Market cap
$937.05M
P/E (TTM)
—
52W range
14.85 – 28.38
Day trading desk
Gap from prior close
-0.52%
Prior close 17.37
VWAP
17.81
-1.72% from price
Relative volume
0.89×
Normal
Session range
7.16%
17.07 – 18.29
Position in range
36%
Mid range
ATR (14D)
1.73
9.89% of price
Prior day high
19.05
PDH
Prior day low
17.18
PDL
Bid / ask spread
—
Quote not published
Session volume
162.22K
Avg 181.78K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-13.21%
-15.1%
1M
-27.24%
-28.7%
3M
-14.65%
-18.0%
6M
—
-14.9%
YTD
-11.77%
-25.7%
1Y
—
-15.7%
3Y
—
-81.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SPTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
18.81M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 22, 26 | HOMBACH ROBERT J. CPA Director |
BUY | 13.00K | $235.77K | Indirect |
| May 4, 26 | PAUL STEVEN M Director |
— | 67.03K | — | Direct |
| May 4, 26 | HEALY JAMES I Director |
— | 2.73M | — | Indirect |
| May 4, 26 | TORRES DENICE Director |
— | 13.41K | — | Indirect |
| May 4, 26 | WHITE LAUREN Chief Financial Officer |
— | 6.70K | — | Indirect |
| May 4, 26 | PURETECH HEALTH PLC Beneficial Owner of more than 10% of a Class of Security |
— | 16.38M | — | Indirect |
| May 4, 26 | ARCH VENTURE PARTNERS XII, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.10M | $19.80M | Indirect |
| May 4, 26 | ARCH VENTURE PARTNERS XII, LLC Beneficial Owner of more than 10% of a Class of Security |
— | 5.19M | — | Indirect |
| May 4, 26 | LOEBEL ANTONY M.D. Officer |
— | 20.11K | — | Direct |
| May 4, 26 | CHEN MICHAEL CUNYUAN PH.D. Officer |
— | 3.35K | — | Direct |
| May 4, 26 | GLADSTEIN LANA J.D. General Counsel |
— | 33.52K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARCH VENTURE PARTNERS XII, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
CHEN MICHAEL CUNYUAN PH.D. |
Officer | 3.35K | Conversion of Exercise of derivative security |
GLADSTEIN LANA J.D. |
General Counsel | 33.52K | Conversion of Exercise of derivative security |
HEALY JAMES I |
Director | — | Conversion of Exercise of derivative security |
HOMBACH ROBERT J. CPA |
Director | — | Purchase |
LOEBEL ANTONY M.D. |
Officer | 20.11K | Conversion of Exercise of derivative security |
PAUL STEVEN M |
Director | 863.03K | Conversion of Exercise of derivative security |
PURETECH HEALTH PLC |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
TORRES DENICE |
Director | — | Conversion of Exercise of derivative security |
WHITE LAUREN |
Chief Financial Officer | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$937.05M
Enterprise value$661.53M
Revenue (TTM)—
Gross profit—
EBITDA$-143.75M
Net income$-134.69M
EPS (TTM)$-5.81
Free cash flow—
Total cash$273.31M
Total debt$5.02M
Book value / share$7.90
Shares outstanding53.53M
Float18.43M
Short % of float6.18%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.80
PEG ratio—
Price / sales—
Price / book2.22
EV / revenue—
EV / EBITDA-4.60
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity1.19
Current ratio18.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $66.31M | $25.07M | +164.5% |
| Selling, general & admin | $20.98M | $27.35M | -23.3% |
| Total operating expense | $87.29M | $52.42M | +66.5% |
| Operating income | -$87.29M | -$52.42M | -66.5% |
| Net interest income | $11.40M | $5.54M | +105.9% |
| Pre-tax income | -$74.11M | -$46.88M | -58.1% |
| Tax provision | $773.00K | $0 | — |
| Net income | -$74.88M | -$46.88M | -59.7% |
| Net income to common | -$74.88M | -$46.88M | -59.7% |
| Basic EPS | -1.94 | -1.21 | -59.9% |
| Diluted EPS | -1.94 | -1.21 | -59.9% |
| EBIT | -$87.29M | -$52.42M | -66.5% |
| EBITDA | -$85.89M | -$52.20M | -64.5% |
| Basic shares | 38.65M | 38.65M | 0.0% |
| Diluted shares | 38.65M | 38.65M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $46.04M | $309.10M | -85.1% |
| Cash & short-term investments | $215.98M | $309.10M | -30.1% |
| Total current assets | $223.23M | $310.15M | -28.0% |
| Property, plant & equipment | $5.22M | $5.17M | +1.0% |
| Total assets | $249.01M | $315.78M | -21.1% |
| Total current liabilities | $12.78M | $11.15M | +14.6% |
| Total debt | $5.08M | $5.01M | +1.5% |
| Total liabilities | $341.55M | $340.63M | +0.3% |
| Retained earnings | -$114.11M | -$39.23M | -190.9% |
| Shareholder equity | -$92.55M | -$24.85M | -272.4% |
| Working capital | $210.45M | $299.00M | -29.6% |
| Net tangible assets | -$92.55M | -$24.85M | -272.4% |
| Shares issued | 53.03M | 53.03M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$74.88M | -$46.88M | -59.7% |
| Depreciation & amortisation | $1.41M | $214.00K | +556.5% |
| Stock-based compensation | $6.88M | $14.52M | -52.6% |
| Change in working capital | -$7.93M | $2.51M | -415.7% |
| Operating cash flow | -$77.94M | -$29.63M | -163.1% |
| Capital expenditure | -$356.00K | -$113.00K | -215.0% |
| Investing cash flow | -$184.25M | -$113.00K | -162,948.7% |
| Financing cash flow | -$873.00K | $339.30M | -100.3% |
| Free cash flow | -$78.30M | -$29.74M | -163.3% |
| End cash position | $46.50M | $309.55M | -85.0% |
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $21.43M | $10.53M | +103.4% |
| Selling, general & admin | $6.11M | $5.65M | +8.2% |
| Total operating expense | $27.54M | $16.18M | +70.2% |
| Operating income | -$27.54M | -$16.18M | -70.2% |
| Net interest income | $2.13M | $3.10M | -31.2% |
| Pre-tax income | -$24.89M | -$13.09M | -90.1% |
| Tax provision | $519.00K | $31.00K | +1,574.2% |
| Net income | -$25.41M | -$13.13M | -93.6% |
| Net income to common | -$25.41M | -$13.13M | -93.6% |
| Basic EPS | -0.48 | -0.34 | -41.1% |
| Diluted EPS | -0.48 | -0.34 | -41.1% |
| EBIT | -$27.54M | -$16.18M | -70.2% |
| EBITDA | -$27.19M | -$15.87M | -71.3% |
| Basic shares | 53.03M | 38.65M | +37.2% |
| Diluted shares | 53.03M | 38.65M | +37.2% |
| Line item | 2026-03-31 | YoY |
|---|---|---|
| Cash & equivalents | $52.91M | |
| Cash & short-term investments | $182.60M | |
| Total current assets | $188.34M | |
| Property, plant & equipment | $5.45M | |
| Total assets | $227.67M | |
| Total current liabilities | $14.22M | |
| Total debt | $5.34M | |
| Total liabilities | $343.29M | |
| Retained earnings | -$139.52M | |
| Shareholder equity | -$115.62M | |
| Working capital | $174.12M | |
| Net tangible assets | -$115.62M | |
| Shares issued | 53.03M |
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Net income | -$25.41M | -$13.13M | -93.6% |
| Depreciation & amortisation | $357.00K | $315.00K | +13.3% |
| Stock-based compensation | $2.57M | $1.62M | +58.7% |
| Change in working capital | $2.53M | -$8.18M | +131.0% |
| Operating cash flow | -$20.17M | -$20.20M | +0.2% |
| Capital expenditure | — | -$54.00K | — |
| Investing cash flow | $27.85M | -$225.55M | +112.3% |
| Financing cash flow | -$783.00K | $0 | — |
| Free cash flow | -$20.17M | -$20.26M | +0.4% |
| End cash position | $53.36M | $63.80M | -16.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.66 | -1.78 | -171.2% |
| Mar 2026 | -3.88 | -10.34 | -166.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.57 | 6 | $0 | — |
| Next quarter | -0.61 | 6 | $0 | — |
| Current year | -5.90 | 6 | $0 | — |
| Next year | -2.57 | 6 | $0 | 0.0% |
Analyst targets & ownership
Mean target$38.29
High target$50.00
Low target$30.00
Implied upside118.71%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold1
Sell / Strong sell0 / 0
Held by insiders35.14%
Held by institutions70.97%
Institutions holding73
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
19.19
-8.77% from price
SMA 20
20.82
-15.91% from price
SMA 50
22.43
-21.95% from price
SMA 100
20.68
-15.37% from price
SMA 200
—
—
EMA 12
19.36
-9.57% from price
EMA 26
20.76
-15.69% from price
EMA 50
21.27
-17.68% from price
RSI (14)
34.5
Neutral
MACD (12,26,9)
-1.40
Hist -0.38
ATR (14)
1.73
9.89% of price
Realised vol 30D
83.4%
Annualised
Bollinger upper
24.87
20, 2σ
Bollinger lower
16.76
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.79
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
83.4%
Annualised
Market vol 1Y
12.2%
SPY, annualised
Max drawdown 1Y
-37.6%
Peak to trough
Max drawdown 5Y
-37.6%
Peak to trough
ATR 14
1.73
9.89% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
3.15M
Prior 3.01M
Change vs prior
+4.5%
Shorts adding
% of float
6.18%
Normal
% of shares out
5.88%
Against total outstanding
Days to cover
22.9
Crowded exit
Float
18.43M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 26 | Raymond James | INITIATED | — | Strong Buy |
| Sep 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 26, 26 | Jones Trading | INITIATED | — | Buy |
| Aug 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 15, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| May 26, 26 | Citigroup | INITIATED | — | Buy |
| May 26, 26 | Leerink Partners | INITIATED | — | Outperform |
| May 26, 26 | JP Morgan | INITIATED | — | Overweight |
| May 26, 26 | Stifel | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-03
Periodic Financial Reports
10-Q · 2026-06-08
Corporate Changes & Voting Matters
8-K · 2026-05-04
Offering Registrations
S-1MEF · 2026-04-30
Trading Registrations
8-A12B · 2026-04-28
Offering Registrations
S-1/A · 2026-04-27
Offering Registrations
S-1 · 2026-04-10
Offering Registrations
DRS/A · 2026-02-27
Headlines
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Business Wire · 3h ago
Seaport Therapeutics Doses First Patient in Phase 2a GlyphAgo Trial
MT Newswires · 8h ago
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Business Wire · 9h ago
Raymond James Initiates Seaport Therapeutics at Strong Buy
MT Newswires · 12d ago
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
GuruFocus.com · 15d ago
PureTech Health H1 Earnings Call Highlights
MarketBeat · 15d ago
Seaport Therapeutics to Participate in September Investor Conferences
Business Wire · 23d ago
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Business Wire · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.